- Home
- PINE vs DMAC Comparison
PINE vs DMAC Comparison
Compare PINE & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINE
- DMAC
- Stock Information
- Founded
- PINE 2019
- DMAC 2000
- Country
- PINE United States
- DMAC United States
- Employees
- PINE N/A
- DMAC N/A
- Industry
- PINE Real Estate Investment Trusts
- DMAC Biotechnology: Pharmaceutical Preparations
- Sector
- PINE Real Estate
- DMAC Health Care
- Exchange
- PINE Nasdaq
- DMAC Nasdaq
- Market Cap
- PINE 220.4M
- DMAC 178.0M
- IPO Year
- PINE 2019
- DMAC N/A
- Fundamental
- Price
- PINE $14.58
- DMAC $3.63
- Analyst Decision
- PINE Strong Buy
- DMAC Strong Buy
- Analyst Count
- PINE 8
- DMAC 2
- Target Price
- PINE $19.00
- DMAC $8.00
- AVG Volume (30 Days)
- PINE 80.6K
- DMAC 325.9K
- Earning Date
- PINE 07-24-2025
- DMAC 08-06-2025
- Dividend Yield
- PINE 7.85%
- DMAC N/A
- EPS Growth
- PINE N/A
- DMAC N/A
- EPS
- PINE 0.07
- DMAC N/A
- Revenue
- PINE $53,967,000.00
- DMAC N/A
- Revenue This Year
- PINE $8.54
- DMAC N/A
- Revenue Next Year
- PINE $3.03
- DMAC N/A
- P/E Ratio
- PINE $195.28
- DMAC N/A
- Revenue Growth
- PINE 14.94
- DMAC N/A
- 52 Week Low
- PINE $14.41
- DMAC $2.98
- 52 Week High
- PINE $19.42
- DMAC $6.82
- Technical
- Relative Strength Index (RSI)
- PINE 40.64
- DMAC 44.55
- Support Level
- PINE $14.42
- DMAC $3.48
- Resistance Level
- PINE $14.89
- DMAC $3.88
- Average True Range (ATR)
- PINE 0.27
- DMAC 0.26
- MACD
- PINE -0.02
- DMAC 0.00
- Stochastic Oscillator
- PINE 18.68
- DMAC 30.10
About PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.